IBBQ — Invesco Nasdaq Biotechnology ETF
Data updated: 2026-07-28
IBBQ — Invesco Nasdaq Biotechnology ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $67.37M AUM · 0.19% expense ratio · 47.6% 1-yr return. From SEC regulatory filings.
IBBQ Fund Overview
IBBQ — Invesco Nasdaq Biotechnology ETF is a US ETF managed by Invesco Exchange-Traded Fund Trust II, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Invesco Exchange-Traded Fund Trust II
- Category: United States Health Care Equity
- Assets under management: $67.37M
- 1-year return: 47.6%
- Ticker: IBBQ
- SEC CIK: 0001378872
- SEC series ID: S000072469
- Share class ID: C000228754
IBBQ Holdings
Top 10 holdings of Invesco Nasdaq Biotechnology ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Invesco Private Prime Fund | 14.20% |
| Gilead Sciences, Inc. | 7.39% |
| Vertex Pharmaceuticals Inc. | 7.38% |
| Amgen Inc. | 7.10% |
| Invesco Private Government Fund | 5.48% |
| Regeneron Pharmaceuticals, Inc. | 5.08% |
| Alnylam Pharmaceuticals, Inc. | 3.19% |
| Revolution Medicines, Inc. | 2.48% |
| Biogen Inc. | 2.29% |
| Illumina, Inc. | 1.98% |
IBBQ Portfolio Allocation
Asset-class allocation of Invesco Nasdaq Biotechnology ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 19.7% |
IBBQ Performance
Total returns for IBBQ (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 5.2% |
| 1 year | 47.6% |
| 3 years (annualised) | 14.5% |
| 5 years (annualised) | 4.0% |
IBBQ Risk Information
Risk metrics for IBBQ, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 13.2%
IBBQ Costs and Fees
IBBQ costs about $19 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.19%
- Gross expense ratio: 0.19%
- Portfolio turnover: 17%
- Brokerage commissions: 0.96 bps of average net assets (SEC N-CEN)
IBBQ Cashflows
Over the 12 months to 2026-02, Invesco Nasdaq Biotechnology ETF had net inflows of $22.65M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-02 | $294.07K |
| 2026-01 | $7.60M |
| 2025-12 | $5.72M |
| 2025-11 | $10.88M |
| 2025-10 | $2.27M |
| 2025-09 | $952.88K |
IBBQ Debt Constituents
No individual debt constituents are reported in Invesco Nasdaq Biotechnology ETF's latest SEC N-PORT filing.
IBBQ Prospectus and SEC Filings
Official Invesco Nasdaq Biotechnology ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.